CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today, LG Chem Life Sciences Innovation Center announced that it has selected Rubik Therapeutics as the winner of their 2022 LabCentral Golden Ticket Program. LabCentral is a first-of-its-kind shared laboratory space designed as a launchpad for high-potential life-sciences and biotech startups located in the heart of Kendall Square in Cambridge, MA.
As a LabCentral sponsor, LG Chem Life Sciences Innovation Center can select a qualifying startup company each year to take up residence in LabCentral’s Kendall Square facility through use of the Golden Ticket. This year is the third year of LG Chem Life Sciences Innovation Center’s Golden Ticket Program and it is designed to assist high-potential and innovative early-stage life science and biotech companies. As LG Chem Life Sciences has announced to focus on Cell and Gene Therapy for future therapeutics, this year’s winner Rubik will have potential strategic fit.
“It is the third Golden Ticket that we have awarded thus far, and we are extremely pleased to have received many strong applications from promising start-ups in the Boston area,” said Peter Hong, President of LG Chem Life Sciences Innovation Center. “We had numerous discussions for the final decision, and considering Cell and Gene Therapy is an exciting and rapidly growing modality in various disease areas, Rubik was made the winner, being aligned with LG Chem Life Sciences’ focused area. Rubik’s mission is to address multiple new solid tumor indications with selective, loss-resistant CAR targets and new class of immune suppression modulators. We believe this unique approach has great potential for next generation cell therapy and we are excited to see the progress being made over the next year.”
Rubik Therapeutics is a platform therapeutics company developing next generation cell therapies for solid tumors. Rubik's computational engine and genome-scale discovery tools have identified a set of unique genetic modulators that can endow immune cells (T and NK) with potent and selective anti-tumor activity. “We are thrilled that LG Chem Life Sciences has recognized the transformative potential of Rubik’s discovery platform to overcome the hurdles that have thus far prevented cell therapies from showing safety, efficacy, and duration of response in solid tumor indications. We look forward to pushing the boundaries of the field along with LG Chem Life Sciences. The Golden Ticket will allow us to continue to advance our programs in a capital-efficient and timely manner,” remarked Murray Robinson, Co-founder and CEO of Rubik.
About LG Chem Life Sciences
LG Chem Life Sciences is a business division within LG Chem, engaged in development, manufacturing, and global commercialization of pharmaceutical products. LG Chem Life Sciences seeks to expand and make global presence by focusing on key core therapeutic areas of Immunology, Oncology, and Metabolic Diseases (specifically, diabetes and related metabolic diseases). To achieve such, its strategy is to actively pursue global collaboration encompassing from asset-centric to strategic investment and collaboration.
About LabCentral
A private, non-profit institution, LabCentral was founded in 2013 as a launchpad for high-potential life sciences and biotech start-ups. Operating a total over 225,000 square-feet in the heart of Kendall Square in Cambridge, Mass., LabCentral offers fully permitted laboratory and office space for as many as 125 start-ups comprising approximately 1,000 scientists and entrepreneurs. More information is available at www.labcentral.org.
About Rubik Therapeutics
Rubik Therapeutics is a seed-stage company focused on developing cell therapies for a range of solid tumors. Rubik is headquartered in Cambridge, MA and backed by Illumina Accelerator.
